Degenerative Disc Disease Clinical Trial Pipeline Strengthens as 15+ Companies Advance 15+ Regenerative and NonSurgical Therapies Toward Market Entry, Finds DelveInsight | Spine BioPharma, Biosplice

DelveInsight's "Degenerative Disc Disease - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies, including include Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes Inc., DiscGenics, Kuros Biosciences, Angitia Biopharmaceuticals, and others developing 15+ pipeline drugs in the Degenerative Disc Disease pipeline landscape.
DelveInsight's "Degenerative Disc Disease - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies developing 15+ pipeline drugs in the Degenerative Disc Disease (DDD) pipeline landscape. It covers pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, development stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Degenerative Disc Disease treatment landscape. Learn more about the evolving Degenerative Disc Disease pipeline today @ https://www.delveinsight.com/report-store/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Degenerative Disc Disease Pipeline Report

*
In August 2025, Spine BioPharma announced topline results from Phase III (MODEL) trial of SB-01 for chronic low back pain due to DDD; met safety endpoints with clinically meaningful pain/function improvements but missed statistical significance on primary endpoint vs. sham.

*
Leading Degenerative Disc Disease companies include Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes Inc., DiscGenics, Kuros Biosciences, Angitia Biopharmaceuticals, and others actively progressing nonsurgical and diseasemodifying options.

*
Promising Degenerative Disc Disease pipeline therapies in various stages of development include SB01, BRTX100, RexlemestrocelL, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, AGA111, CybroCell, GQ401, DiscSeal, rhGDF5, HST 004, and additional candidates expected to influence the treatment paradigm in the coming years.

Download for updates and emerging trends @ Degenerative Disc Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Degenerative Disc Disease Emerging Drugs Profile

*
SB01: Spine BioPharma, Inc.

SB01 is a synthetic 7amino acid peptide designed to bind to and antagonize transforming growth factor beta 1 (TGF1), an inflammatory cytokine that is often highly expressed in degenerated intervertebral discs and linked to extracellular matrix breakdown, inflammation, and discogenic pain. Delivered as a single intradiscal injection into the diseased lumbar disc, SB01 is intended to decrease TGF1mediated catabolism, reduce pain, and promote restoration of disc structural integrity, and it is currently being evaluated in a Phase III clinical program (MODEL trial) for degenerative disc disease-associated chronic low back pain.

*
BRTX100: BioRestorative Therapies

BRTX100 is a novel autologous cellbased therapy formulated from a patient's own hypoxic, cultured mesenchymal stem cells derived from bone marrow and combined with autologous platelet lysate. Administered via a minimally invasive intradiscal injection in an outpatient setting, BRTX100 is being developed for patients with painful lumbosacral disc degeneration whose symptoms are not adequately controlled by conservative measures and who may otherwise progress toward surgery, and it is currently in a randomized Phase 2 trial and has received FDA Fast Track designation for chronic lumbar disc disease.

For more information on the Degenerative Disc Disease Emerging Drugs Profile, download DelveInsight's comprehensive Degenerative Disc Disease Pipeline Insight report [https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The Degenerative Disc Disease Pipeline Report Provides

*
Detailed insights about companies developing therapies for Degenerative Disc Disease, including the aggregate number of therapies in their portfolios and the relative advancement of each program.

*
Different therapeutic candidates segmented into earlystage, midstage, and latestage of development for Degenerative Disc Disease treatment, spanning Phase III, Phase II, Phase I, preclinical, discovery, and discontinued or inactive projects.

*
Degenerative Disc Disease companies involved in targeted therapeutics development, with clear distinction between active, dormant, and discontinued assets to support competitive benchmarking and opportunity assessment.

*
Degenerative Disc Disease drugs under development categorized by stage of development, route of administration, target or mechanism, monotherapy or combination status, and molecular type, enabling multidimensional pipeline analytics.

*
Detailed analysis of collaborations (industry-industry and industry-academia), licensing deals, mergers and acquisitions, financing rounds, and regulatory designations that shape the commercial trajectory of emerging Degenerative Disc Disease therapies.

Learn more about Degenerative Disc Disease drugs opportunities in our groundbreaking research and development projects @ Degenerative Disc Disease Unmet Needs [https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Degenerative Disc Disease Companies

There are 15+ key companies developing therapies for Degenerative Disc Disease, including Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes Inc., DiscGenics, Kuros Biosciences, Angitia Biopharmaceuticals, and others focused on regenerative, biologic, and minimally invasive solutions for chronic low back pain and disc degeneration.

According to DelveInsight's assessment, Spine BioPharma's SB01 represents one of the most advanced pharmacologic programs in the Degenerative Disc Disease space, while cellbased and genemodulating therapies from players such as BioRestorative Therapies, Mesoblast, DiscGenics, and Angitia Biopharmaceuticals diversify the late and midstage pipeline.

DelveInsight's Degenerative Disc Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Degenerative Disc Disease products have been categorized under various Molecule types such as:

*
Monoclonal antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Scope of the Degenerative Disc Disease Pipeline Report

*
Coverage: Global

*
Degenerative Disc Disease companies: Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes Inc., DiscGenics, Kuros Biosciences, Angitia Biopharmaceuticals, and other biotechnology and pharmaceutical innovators.

*
Degenerative Disc Disease Therapies: SB01, AGA111, RexlemestrocelL, BRTX100, IDCT, Lorecivivint, AMG0103, CybroCell, GQ401, CWT 002, DiscSeal, rhGDF5, HST 004, and others that collectively target inflammation, catabolic signaling, disc biology, and structural restoration.

*
Degenerative Disc Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination, enabling differentiation of standalone therapies from those being positioned as adjuncts or combination regimens.

*
Degenerative Disc Disease Therapeutic Assessment by Clinical Stages: Discovery, Preclinical, Phase I, Phase II, Phase III, and discontinued or inactive candidates, supporting strategic evaluation of nearterm launch candidates and longerterm innovation opportunities.

For a detailed overview of our latest research findings, read the full details of the Degenerative Disc Disease Pipeline @ Degenerative Disc Disease Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Table of Contents

*
Introduction

*
Executive Summary

*
Degenerative Disc Disease: Overview

*
Pipeline Therapeutics

*
Therapeutic Assessment

*
Degenerative Disc Disease - DelveInsight's Analytical Perspective

*
Late Stage Products (Phase III)

*
Mid Stage Products (Phase II)

*
Early Stage Products (Phase I)

*
Preclinical and Discovery Stage Products

*
Inactive Products

*
Degenerative Disc Disease Key Companies

*
Degenerative Disc Disease Key Products

*
Degenerative Disc Disease Unmet Needs

*
Degenerative Disc Disease Market Drivers and Barriers

*
Degenerative Disc Disease Future Perspectives and Conclusion

*
Degenerative Disc Disease Analyst Views

*
Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=degenerative-disc-disease-clinical-trial-pipeline-strengthens-as-15-companies-advance-15-regenerative-and-nonsurgical-therapies-toward-market-entry-finds-delveinsight-spine-biopharma-biosplice]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.